Celonic and Carbogen Amcis Form Strategic Alliance for Integrated ADC Development and Manufacturing
核心洞察
Celonic Group (搜索) and Carbogen Amcis Group (搜索) have announced a strategic partnership to offer fully integrated antibody-drug conjugate development and manufacturing solutions.
The alliance combines Celonic's advanced biologics capabilities with Carbogen Amcis's expertise in payload synthesis, conjugation, and sterile fill-finish operations.
This partnership addresses critical industry needs by streamlining supply chains and reducing complexity for ADC innovators from early development through commercial launch.
Celonic Group (搜索), a biologics contract development and manufacturing organization (CDMO), and Carbogen Amcis Group (搜索), a pharmaceutical process development and active pharmaceutical ingredient manufacturing company, have formed a strategic alliance to deliver fully integrated antibody-drug conjugate (ADC) development and manufacturing solutions. The partnership creates a seamless, end-to-end platform designed to address the complex needs of ADC innovators in the rapidly growing targeted cancer (搜索) therapy market.
Addressing Industry Complexity
The collaboration directly responds to a critical challenge in the biopharmaceutical sector, where ADC development complexity typically requires coordination between multiple vendors. By combining their complementary expertise, the companies aim to streamline supply chains, accelerate development timelines, and support clients from early-stage research through commercial launch.
"This strategic alliance is a direct response to the evolving needs of ADC innovators," said Dr. Samanta Cimitan, CEO of Celonic Group (搜索). "By integrating Celonic's advanced biologics platforms with CARBOGEN AMCIS's world-class payload and conjugation capabilities, we're enabling a fully harmonized development and manufacturing pathway, from DNA to drug product. It's a scalable, compliant, and commercially ready solution designed to accelerate innovation and reduce complexity for our partners."
Comprehensive Service Portfolio
The integrated offering encompasses the complete ADC development and manufacturing spectrum. Celonic contributes cell line development and antibody production capabilities at scale, while Carbogen Amcis provides payload and linker synthesis, large-scale manufacturing, ADC conjugation, and sterile fill-finish services. The partnership also includes regulatory support and chemistry, manufacturing, and controls (CMC) documentation for Investigational New Drug (IND), Investigational Medicinal Product Dossier (IMPD), and Biologics License Application (BLA) filings.
Stephan Fritschi, CEO of Carbogen Amcis Group (搜索), emphasized the market drivers behind the alliance: "The new targeted cancer (搜索) treatments have fueled a rising demand for ADCs, and this alliance positions us to meet that demand with unmatched technical expertise and operational agility. Together, we offer a comprehensive service for ADC development, streamlined, scalable, and globally compliant."
Established Expertise and Infrastructure
Carbogen Amcis brings significant ADC experience to the partnership, having delivered its first ADC project in 2005 and subsequently supporting numerous programs across payload, linker, conjugation, and sterile drug product development. The company operates dedicated conjugation suites in Switzerland and maintains clinical-to-commercial and commercial manufacturing capabilities for sterile liquid drug products at an ANMS-approved facility in France.
Celonic Group (搜索) has recently expanded its infrastructure, including enhancements to its Biologics Development Center in Basel and GMP manufacturing site in Heidelberg. These expansions incorporate high-yield GS-CHOvolution™ cell line platforms, enhanced perfusion-based technologies for process optimization, and commercial-scale biomanufacturing suites.
Innovation and Future Capabilities
Arpit Vyas, Global Managing Director of Dishman and Carbogen Amcis Group (搜索), highlighted the partnership's potential for innovation: "For more than 2 decades now we've been the preferred partner for linker & payload development and until now, with customer supplied monoclonal antibodies (搜索), precise conjugation. We are excited that henceforth, through our partnership with Celonic, innovators will now get a seamless, end-to-end ADC path—from cell line to commercial fill-finish—under one coordinated platform."
The companies are also evaluating advanced manufacturing technologies, including continuous-flow conjugation using custom micro-equipment skids designed to maintain precise control over pH, temperature, stoichiometry, and residence time parameters.
Streamlined Operations
The alliance structure positions Celonic as the upstream partner and Carbogen Amcis as the downstream partner, providing clients with a single accountable partner throughout the development process. This integrated approach is designed to eliminate variability and reduce handoffs, potentially accelerating the delivery of life-saving therapies to patients globally.